Which factor contributes to gaps in current drug therapy dosage guidelines?

Which factor contributes to gaps in current drug therapy dosage guidelines?

• A. Means and medians derived from highly diverse populations.
• B. Means and medians derived from clinical trials, which are relatively homogeneous populations (mostly Caucasian adults with no comorbidities).
• C. Post-marketing surveillance data immediately adjusting dose recommendations.
• D. Randomized trials across multiple species.

Answer: (B)

Dosing guidelines are built from clinical trial data, and those trials often enroll a relatively homogeneous group—mostly Caucasian adults with no comorbidities. The averages and medians from such a narrow sample don’t reflect the diversity of real patients, so the recommended doses may not be appropriate for people who differ in age, sex, ethnicity, organ function, pregnancy status, or who have other health conditions or take multiple medications. Differences in pharmacokinetics and pharmacodynamics—how the body processes a drug and how it responds to it—mean the same dose can lead to under- or overexposure in different individuals. Averages hide this variability, creating gaps when applying guidelines broadly. Post-marketing surveillance can help update dosing as real-world data accumulate, but the initial gap mainly stems from trial populations not representing the full patient population. Cross-species randomized data isn’t how human dosing is determined.

Dosing guidelines are built from clinical trial data, and those trials often enroll a relatively homogeneous group—mostly Caucasian adults with no comorbidities. The averages and medians from such a narrow sample don’t reflect the diversity of real patients, so the recommended doses may not be appropriate for people who differ in age, sex, ethnicity, organ function, pregnancy status, or who have other health conditions or take multiple medications. Differences in pharmacokinetics and pharmacodynamics—how the body processes a drug and how it responds to it—mean the same dose can lead to under- or overexposure in different individuals. Averages hide this variability, creating gaps when applying guidelines broadly. Post-marketing surveillance can help update dosing as real-world data accumulate, but the initial gap mainly stems from trial populations not representing the full patient population. Cross-species randomized data isn’t how human dosing is determined.